GlaxoSmithKline Pharmaceuticals Limited
GLAXO
株式のランク
#3775
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
株価
$25.73
時価総額
$4.36B
変化（1日）
-5.33%
変化（1年）
-17.92%
国
IN
取引 GlaxoSmithKline Pharmaceuticals Limited (GLAXO)
カテゴリー
Healthcare
GlaxoSmithKline Pharmaceuticals Limited（GLAXO）の株価履歴
終値の最高値: $28.33 （2026-10-01）
終値の最安値: $7.46 （1999-01-01）
終値の最安値: $7.46 （1999-01-01）
GlaxoSmithKline Pharmaceuticals Limited の株価履歴（1999 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -0.80% |
| 2025 | 3.53% |
| 2024 | 30.13% |
| 2023 | 28.84% |
| 2022 | -31.26% |
| 2021 | 11.05% |
| 2020 | -8.11% |
| 2019 | 15.01% |
| 2018 | 5.68% |
| 2017 | -5.61% |
| 2016 | -18.58% |
| 2015 | 0.11% |
| 2014 | 11.37% |
| 2013 | 16.93% |
| 2012 | 5.11% |
| 2011 | -25.99% |
| 2010 | 39.42% |
| 2009 | 47.96% |
| 2008 | -8.92% |
| 2007 | -0.02% |
| 2006 | 7.37% |
| 2005 | 41.03% |
| 2004 | 38.71% |
| 2003 | 85.99% |
| 2002 | 3.08% |
| 2001 | -33.62% |
| 2000 | -42.61% |
| 1999 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $1.31K | 61.05% |
US
|
|
| $269.04 | 39.44% |
US
|
|
| $284.39 | 24.36% |
US
|
|
| $147.01 | 67.79% |
US
|
|
| $482.01 | 30.76% |
CH
|
